SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mr. Forthright who wrote (1468)	6/20/1998 1:05:00 AM
From: chirodoc	of 5402

HELPS TO REDUCE INFECTION IN WOUNDS Vestn Khir Im I I Grek 1997;156(4):53-55 [The use of a perfluorocarbon emulsion in the local treatment of wounds complicated by a surgical infection]. Khrupkin VI, Moroz VV, Pisarenko LV, Khomenchuk AI The article shows effectiveness of the local application of Perftoran in complex treatment of purulent wounds of soft tissues in 50 patients. Perftoran has no necrolytic and antibacterial properties and fails to make the terms of the 1st phase of the wound process shorter. Perftoran maintains the intensified development of young cell elements at different periods of healing of the purulent wounds, decreases the propagation of microorganisms in them, lessens the wound square surface, results in earlier development of marginal epithelialization and formation of the elastic cicatrix.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next